Boule Diagnostics AB is a company with a strong heritage when it comes to hematology diagnostics. We developed the very first European blood cell counter, and today our instruments, reagents, calibrators and controls are used by healthcare providers around the world. Boule’s products are currently on sale in more than 100 countries.
Our blood tests help provide one of the first and most important indicators of a disease state and Boule systems play an increasingly important role in helping build the infrastructure of healthcare for small and medium size patient care environments in both human and veterinary markets.
Boule is listed on NASDAQ Stockholm since June 2011.
Interview with Boules CEO Fredrik Dalborg answering questions about the third quarter 2017.
Net sales, SEK million
(increased by 21%)
(increased by 118%)
(increased by 4%)
(increased by 5%)